Managing Opportunities And Risks In Generative AI Use For Clinical Research

By The Editors of the Insights Hub, PPD clinical research business of Thermo Fisher Scientific

The arrival of generative AI in life sciences feels like a "once-in-a-generation" shift, promising to turn the tide on everything from protocol optimization to pharmacovigilance. However, the path from experimental potential to clinical reality is paved with significant regulatory friction. Unlike traditional AI models—which are often task-specific and predictable—generative AI is non-deterministic and built on opaque datasets, creating a fundamental mismatch with current FDA and EMA frameworks that prioritize reproducibility and clear data provenance.

Bridging this gap requires moving beyond the "human in the loop" interim fix, which often leads to oversight fatigue and cognitive drift. True progress lies in a more robust ecosystem of adversarial AI agents, active learning loops, and a workforce trained in high-level digital literacy. By shifting the perspective of AI from a simple automation tool to a dynamic team member that requires continuous lifecycle assessment, the industry can begin to satisfy stringent safety standards. Exploring these strategies reveals how we can move past the hype of "hallucinations" toward a governed, scalable framework that enhances human judgment and accelerates the delivery of life-saving therapies.